AMRZ vs MLM

The company exhibits a Piotroski F-Score of 4/9, indicating stable but not robust financial health, while the absence of an Altman Z-Score limits distress risk assessment. Valuation metrics suggest the stock trades at a premium to both the Graham Number ($35.19) and intrinsic value ($16.52), supported by a high P/E of 22.98 versus sector peers. Despite solid operating margins and manageable leverage, earnings growth is negative year-over-year and quarterly earnings surprises have been inconsistent. Analysts recommend a 'buy' with a target price of $60.08, implying upside, but weak recent price performance and lack of dividend or insider activity temper near-term conviction.

MLM exhibits a stable but mediocre financial health profile with a Piotroski F-Score of 4/9 and no available Altman Z-Score. The stock is severely overvalued, trading at $612.85, which is more than double its Graham Number ($247.45) and over five times its growth-based intrinsic value ($114.52). While revenue shows modest growth, earnings are trending downward both YoY (-4.10%) and Q/Q (-5.10%), creating a dangerous disconnect between price and fundamental performance. The bearish technical trend (0/100) further suggests a lack of market momentum to support these premium valuations.